CR845: Phase II data

A double-blind, U.S. Phase II trial in 203 women undergoing a laparoscopic hysterectomy showed that a pre- and post-operative dose of 0.04 mg/kg IV CR845 met the primary endpoint of reducing total morphine consumption over the first 24 hours post-surgery vs. pre- and post-operative placebo. Specifically, pre- and post-operative CR845 reduced total morphine consumption by about 33% vs. placebo (p<0.05). On secondary endpoints, pre- and post-operative CR845 significantly increased 24-hour PID and SPID by about 100% vs. placebo (p=0.002 and p=0.003, respectively). Additionally, a single post-operative dose of 0.04 mg/kg IV CR845 significantly increased 24-hour SPID by >50% vs. placebo (p=0.014). ...